A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
Price : $35 *
At a glance
- Drugs Dovitinib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms DOVE-M
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.
- 21 May 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 15 Aug 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.